Evidence map›Paper›PMID 41229547›Full record

ReviewInternational journal of general medicine2025

Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review.

Xue Chen

Abstract readReview
In one paragraph

Review in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. AAntioxidants (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Xue ChenSchool of Medicine, Lishui University, Lishui, Zhejiang, People's Republic of China.ORCID 0009-0000-8642-256X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by impaired skin barrier function and immune dysregulation. Despite advancements in understanding its pathogenesis, clinical management remains challenging due to high recurrence rates, complex symptom control, and diminished quality of life, particularly highlighting the lack of standardized protocols for skin barrier repair. Compromised skin barrier integrity in AD leads to increased transepidermal water loss (TEWL) and heightened susceptibility to irritants and allergens, exacerbating inflammation. Thus, restoring skin barrier function is pivotal in AD management. Current therapeutic strategies predominantly prioritize anti-inflammatory treatments while undervaluing barrier repair. Traditional care models relying on qualitative symptom assessments inadequately guide personalized interventions, necessitating an integrated approach combining barrier restoration and immunomodulation. Although diverse barrier repair methods and moisturizers are available, systematic evaluation and evidence-based selection criteria remain limited. This review aims to comprehensively summarize the structure and function of the skin barrier in AD, the role of skin barrier dysfunction in AD pathogenesis, current barrier repair strategies, and evidence-based emollient selection criteria. By analyzing existing research, we provide clinical recommendations for skin barrier restoration and long-term management in AD patients, while proposing future research directions. Emphasis should be placed on developing multi-omics-driven personalized barrier interventions and constructing a "barrier-immune-environment" interaction model to advance precision medicine in AD care.

Indexed as

emollientsimmune dysregulationmoisturizersskin managementtherapeutic strategiestransepidermal water loss

Identifiers

PMID41229547
PMCPMC12604518

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.